Search results
1 lut 2011 · A total of 29 new molecular entities, vaccines, and blood products won FDA marketing approval last year, down from 38 in the previous year. Highlights of the approved products appear below, and a full list of new products and their indications appears on page 188.
This Briefing presents the results from the Centre for Innovation in Regulatory Science (CIRS) annual analysis of New Active Substance (NAS) approvals by six major regulatory agencies: the European Medicines Agency (EMA), the US Food and Drug Administration (FDA), the Japan Pharmaceuticals and Medical Devices Agency (PMDA), Health Canada, Swissm...
Underlying factors influencing the overall time it takes for a new medicine to be submitted and then approved by an agency include company strategy, the conduct and the type of the review process, the type of the product and its therapeutic area; these aspects are analysed and discussed in this study.
This Briefing presents the results from the Centre for Innovation in Regulatory Science (CIRS) annual analysis of New Active Substance (NAS) approvals by six major regulatory agencies: the European Medicines Agency (EMA), the US Food and Drug Administration (FDA), the Japan Pharmaceuticals and Medical Devices Agency (PMDA), Health Canada, Swissm...
28 kwi 2023 · Using a data set of drugs approved from 2010 to 2019 (before the COVID-19 pandemic), this analysis estimated the NIH investment in these drugs, including the cost of published basic and applied research associated with these products, cost of phased clinical trials of failed product candidates, and opportunity cost, using discount rates ...
11 mar 2021 · Abstract. A total of 378 novel drugs and 27 biosimilars approved by the U.S. Food and Drug Administration (FDA) between 2010 and 2019 were evaluated according to approval numbers by year, therapeutic areas, modalities, route of administration, first-in-class designation, approval times, and expedited review categories.
Asher Mullard. The US Food and Drug Administration’s (FDA’s) Center for Drug Evaluation and Research (CDER) approved 15 new molecular entities and 6 new biologics in 2010. The total of 21...
